Misonix (MSON) 10-Q 5 Feb 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Dec. 31, 2013	Feb. 05, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'MISONIX INC	'
Entity Central Index Key	'0000880432	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'MSON	'
Entity Common Stock, Shares Outstanding	'	7,234,536
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$5,033,526	$5,806,437
Accounts receivable, less allowance for doubtful accounts of $244,641 and $214,641, respectively	2,870,988	2,974,641
Inventories, net	3,969,972	4,034,477
Prepaid expenses and other current assets	209,898	387,371
Total current assets	12,084,384	13,202,926
Property, plant and equipment, net	1,304,998	1,326,586
Goodwill	1,701,094	1,701,094
Intangible and other assets	1,030,995	1,129,321
Total assets	16,121,471	17,359,927
Current liabilities:	'	'
Accounts payable	1,154,838	2,208,999
Accrued expenses and other current liabilities	1,062,988	1,276,963
Total current liabilities	2,217,826	3,485,962
Deferred lease liability	20,212	23,811
Deferred income	75,072	72,934
Total liabilities	2,313,110	3,582,707
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Common stock, $.01 par value-shares authorized 20,000,000, 7,274,596 and 7,233,884 shares issued and 7,197,036 and 7,156,324 shares outstanding, respectively	72,746	72,339
Additional paid-in capital	27,444,957	26,989,559
Accumulated deficit	-13,298,349	-12,873,685
Treasury stock, at cost, 77,560 shares	-410,993	-410,993
Total stockholders' equity	13,808,361	13,777,220
Total liabilities and stockholders' equity	$16,121,471	$17,359,927

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Allowance for doubtful accounts (in dollars)	$244,641	$214,641
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	7,274,596	7,233,884
Common stock, shares outstanding	7,197,036	7,156,324
Treasury stock, shares	77,560	77,560

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net sales	$4,122,059	$3,474,231	$7,197,643	$8,044,756
Cost of goods sold	1,229,409	1,626,965	2,574,739	3,470,864
Gross profit	2,892,650	1,847,266	4,622,904	4,573,892
Operating expenses:	'	'	'	'
Selling expenses	1,683,699	1,545,585	3,512,529	3,004,149
General and administrative expenses	1,120,926	1,092,726	2,342,241	2,135,058
Research and development expenses	435,019	366,257	907,907	763,388
Total operating expenses	3,239,644	3,004,568	6,762,677	5,902,595
Loss from operations	-346,994	-1,157,302	-2,139,773	-1,328,703
Other income (expense):	'	'	'	'
Interest income	19	25	38	38
Royalty income and license fees	809,392	522,385	1,722,186	745,064
Royalty expense	0	-1,415	0	-5,113
Other	-5,304	-18,608	-11,565	-26,185
Total other income	804,107	502,387	1,710,659	713,804
Income/(loss) from continuing operations before income taxes	457,113	-654,915	-429,114	-614,899
Income tax expense	2,750	2,329	5,500	3,829
Net income/(loss) from continuing operations	454,363	-657,244	-434,614	-618,728
Discontinued operations:	'	'	'	'
Income from discontinued operations net of tax expense of $0 and $0, respectively	4,975	3,475	9,950	9,793
Net income from discontinued operations	4,975	3,475	9,950	9,793
Net income/(loss)	$459,338	($653,769)	($424,664)	($608,935)
Net income/(loss) per share from continuing operations - Basic (in dollars per share)	$0.06	($0.09)	($0.06)	($0.09)
Net income per share from discontinued operations - Basic (in dollars per share)	$0	$0	$0	$0
Net income/(loss) per share - Basic (in dollars per share)	$0.06	($0.09)	($0.06)	($0.09)
Net income/(loss) per share from continuing operations - Diluted (in dollars per share)	$0.06	($0.09)	($0.06)	($0.09)
Net income per share from discontinued operations - Diluted (in dollars per share)	$0	$0	$0	$0
Net income/(loss) per share - Diluted (in dollars per share)	$0.06	($0.09)	($0.06)	($0.09)
Weighted average shares - Basic (in shares)	7,195,406	7,020,107	7,189,136	7,012,734
Weighted average shares - Diluted (in shares)	7,712,903	7,020,107	7,189,136	7,012,734

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income from discontinued operations net of tax expense	$0	$0	$0	$0

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Jun. 30, 2013	$13,777,220	$72,339	($410,993)	$26,989,559	($12,873,685)
Balance (in shares) at Jun. 30, 2013	'	7,233,884	-77,560	'	'
Net loss/comprehensive loss	-424,664	0	0	0	-424,664
Proceeds from exercise of stock options	130,555	407	0	130,148	0
Proceeds from exercise of stock options (in shares)	'	40,712	0	'	'
Stock-based compensation	325,250	0	0	325,250	0
Balance at Dec. 31, 2013	$13,808,361	$72,746	($410,993)	$27,444,957	($13,298,349)
Balance (in shares) at Dec. 31, 2013	'	7,274,596	-77,560	'	'

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Common Stock, Par Value (in dollars per share)	$0.01	$0.01

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating activities	'	'
Net loss from continuing operations	($434,614)	($618,728)
Adjustments to reconcile net loss to net cash (used in)/ provided by continuing operating activities:	'	'
Depreciation and amortization and other non-cash items	459,449	365,092
Bad debt expense	30,000	28,902
Stock-based compensation	325,250	220,979
Deferred income	-3,655	-22,106
Deferred lease liability	-3,599	407
Changes in operating assets and liabilities:	'	'
Accounts receivable	73,653	800,649
Inventories	40,631	206,376
Prepaid expenses and other assets	226,765	163,306
Accounts payable, accrued expenses and other non-cash items	-1,262,343	-438,811
Net cash (used in)/provided by operating activities	-548,463	706,066
Investing activities	'	'
Acquisition of property, plant and equipment	-292,945	-134,908
Additional patents	-72,008	-42,775
Net cash used in investing activities	-364,953	-177,683
Financing activities	'	'
Proceeds from exercise of stock options	130,555	43,856
Net cash provided by financing activities	130,555	43,856
Cash flows from discontinued operations	'	'
Net cash provided by operating activities	9,950	9,793
Net cash provided by discontinued operations	9,950	9,793
Net (decrease)/increase in cash and cash equivalents	-772,911	582,032
Cash and cash equivalents at beginning of period	5,806,437	6,273,015
Cash and cash equivalents at end of period	5,033,526	6,855,047
Supplemental disclosure of cash flow information:	'	'
Income taxes	$11,450	$11,449

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	1. Basis of Presentation
	The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the year ended June 30, 2013 (“2013 Annual Report”) of MISONIX, INC. (“Misonix” or the “Company”). A summary of the Company’s significant accounting policies is identified in Note 1 of the notes to the consolidated financial statements included in the Company’s 2013 Annual Report. There have been no changes in the Company’s significant accounting policies subsequent to June 30, 2013.
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X pursuant to the requirements of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the interim periods are not necessarily indicative of the results of operations for the entire year.
	The consolidated financial statements of the Company include the accounts of Misonix and its 100% owned subsidiaries, Fibra-Sonics (NY) Inc. and Hearing Innovations, Inc. All significant intercompany balances and transactions have been eliminated.
	Organization and Business
	Misonix is a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications.
	The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made primarily through distributors. Sales made in the United States are made primarily through representative agents. The following is an analysis of net sales from continuing operations by geographic region:
		Three months ended December 31,						Six months ended December 31,
		2013		2012				2013			2012
	United States	$	1,827,543	$	1,635,550	United States		$	3,408,813		$	4,085,160
	Australia		32,013		141,774	Australia			75,353			281,674
	Europe		369,701		958,388	Europe			753,291			1,720,299
	Asia		870,793		361,556	Asia			1,337,060			783,783
	Canada and Mexico		347,640		29,922	Canada and Mexico			432,345			255,982
	South America		434,983		108,462	South America			710,604			406,388
	South Africa		72,118		105,584	South Africa			165,694			312,267
	Middle East		167,268		132,995	Middle East			314,483			199,203
		$	4,122,059	$	3,474,231			$	7,197,643		$	8,044,756
	Discontinued Operations
	Laboratory and Forensic Safety Products Business
	On October 19, 2011, Misonix sold its Laboratory and Forensic Safety Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The earn-out will not be factored into the gain on sale until it is earned by Misonix. As of December 31, 2013, no earn-out has been recorded.
	High Intensity Focused Ultrasound Technology
	In consideration for the May 2010 sale of the rights to its high intensity focused ultrasound technology to USHIFU LLC (“USHIFU”), Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received by USHIFU related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to the $5.8 million. Commencing 90 days after each December 31stand beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Total payments through December 31, 2013 were $504,788.
	Results of Discontinued Operations
		For the three months ended				For the six months ended
		December 31,				December 31,
		2013		2012		2013			2012
	Revenues	$	4,975	$	4,975	$	9,950		$	9,950
	Income from discontinued operations, before tax	$	4,975	$	3,475	$	9,950		$	9,793
	Income tax expense		-		-		-			-
	Net income from discontinued operations, net of tax	$	4,975	$	3,475	$	9,950		$	9,793
	Accounts Receivable
	Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.
	Reclassifications
	Certain prior period amounts in the accompanying financial statements and related notes have been reclassified to conform to the current period’s presentation.

Income_Loss_Per_Share_of_Commo

Income (Loss) Per Share of Common Stock	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	2. Income (Loss) Per Share of Common Stock
	Basic net income (loss) per common share (“basic EPS”) is computed by dividing income (loss) by the weighted average number of common shares outstanding for the period. Diluted income/(loss) per common share (“diluted EPS”) is computed by dividing income (loss) by the weighted average number of common shares and dilutive common share equivalents outstanding (consisting of outstanding common stock options) for the period.
	The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:
		For the six months ended		For the three months ended
		December 31,		December 31,
		2013	2012	2013	2012
	Basic shares	7,189,136	7,012,734	7,195,406	7,020,107
	Dilutive effect of stock options	-	-	517,497	-
	Diluted shares	7,189,136	7,012,734	7,712,903	7,020,107
	Excluded from the calculations of diluted EPS are options to purchase 543,080 shares of common stock for the three months ended December 31, 2013. The excluded shares are any share for which the average stock price for the quarter or year–to-date is less than the exercise price of the outstanding options in the period in which the Company has net income.
	Diluted EPS for the six months ended December 31, 2013 and six and three months ended December 31, 2012 presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of diluted EPS are outstanding options to purchase 1,831,829 and 1,922,905 shares of common stock for the six months ended December 31, 2013 and the three and six months ended December 31, 2012, respectively.

Comprehensive_LossIncome

Comprehensive (Loss)/Income	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	3. Comprehensive (Loss)/Income
	Total comprehensive loss, which includes results of discontinued operations, was $424,664 and $608,935 for the six months ended December 31, 2013 and 2012, respectively. Total comprehensive gain/(loss) was $459,338 and $(653,769) for the three month period ended December 31, 2013 and 2012, respectively. There are no components of comprehensive (loss)/income other than net (loss)/income for all periods presented.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	4. Stock-Based Compensation
	Stock options are granted with exercise prices not less than the fair market value of our common stock at the time of the grant, with an exercise term (as determined by the committee administering the applicable option plan (the “Committee”)) not to exceed 10 years. The Committee determines the vesting period for the Company’s stock options. Generally, such stock options have vesting periods of immediate to four years. Certain option awards provide for accelerated vesting upon meeting specific retirement, death or disability criteria and upon a change in control. During the six month periods ended December 31, 2013 and 2012, the Company granted options to purchase 324,000 and 342,500 shares of the Company’s common stock, respectively.
	Stock-based compensation expense for the six month periods ended December 31, 2013 and 2012 was approximately $325,000 and $221,000, respectively. Compensation expense is recognized in the general and administrative expenses line item of the Company’s consolidated statements of operations on a straight-line basis over the vesting periods. As of December 31, 2013, there was approximately $2,143,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements to be recognized over a weighted-average period of 3.2 years.
	Cash in the amount of $130,555 was received from the exercise of stock options for the six months ended December 31, 2013.
	The fair values of the options granted during the six months ended December 31, 2013 and 2012 were estimated on the date of the grant using the Black-Scholes option-pricing model on the basis of the following weighted average assumptions during the respective periods:
			For the six months ended
			December 31,
			2013				2012
	Risk-free interest rate			3	%			2.5	%
	Expected option life in years			6.5				6.5
	Expected stock price volatility			76.09	%			75.1	%
	Expected dividend yield			0	%			0	%
	Weighted-average fair value of options granted		$	3.95			$	2.94
	The expected option term is based upon the number of years the Company estimates the option will be outstanding based on historical exercises and terminations. The expected volatility for the expected life of the options is determined using historical price changes of the Company’s stock over a period equal to that of the expected life of the options. The risk free rate is based upon the U.S. Treasury yield in effect at the time of the grant. The expected dividend yield is 0% as the Company has historically not declared dividends and does not expect to declare any in the future.
	Changes in outstanding stock options during the six months ended December 31, 2013 were as follows:
			Options
						Weighted
						Average
				Weighted		Remaining
				Average		Contractual		Aggregate
			Number of	Exercise		Life		Intrinsic
			Shares	Price ($)		(years)		Value (a)
	Outstanding as of June 30, 2013		1,729,991	3.65
	Granted		324,000	4.94
	Exercised		-40,712	3.21
	Forfeited		-19,250	4.64
	Expired		-162,200	4.67
	Outstanding as of December 31, 2013		1,831,829	3.78		5.6		$	3,644,848
	Exercisable and vested at December 31, 2013		1,101,555	3.68		4.3		$	2,353,430
	Available for grant at December 31, 2013		549,975
	(a)	Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at December 31, 2013 or if exercised, the exercise dates, exceeds the exercise prices of the respective options.

Income_Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	5. Income Taxes
	For the six months ended December 31, 2013, the Company recorded an income tax expense in continuing operations of $5,500.
	For the six months ended December 31, 2013 and 2012, the effective rate of (1%) on continuing operations varied from the U.S. federal statutory rate primarily due to permanent book tax differences, state taxes and a change in the valuation allowance.
	The Company established a valuation against the deferred tax asset in prior years when management concluded that it is more likely than not that the deferred tax asset may not be fully realized. Management’s deferred tax asset assessment is unchanged as of December 31, 2013.
	As of December 31, 2013 and June 30, 2013, the Company has no material unrecognized tax benefits or accrued interest and penalties.

Inventories

Inventories	6 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	6. Inventories
	Inventories are summarized as follows:
		December 31,		June 30,
		2013		2013
	Raw material	$	2,029,216	$	2,641,982
	Work-in-process		604,841		394,629
	Finished goods		2,797,511		2,358,943
			5,431,568		5,395,554
	Less valuation reserve		1,461,596		1,361,077
		$	3,969,972	$	4,034,477

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	'
	7. Accrued Expenses and Other Current Liabilities
	The following summarizes accrued expenses and other current liabilities:
		December 31,		June 30,
		2013		2013
	Accrued payroll and vacation	$	406,279	$	456,095
	Accrued bonuses		100,000		225,000
	Accrued commissions		208,000		200,678
	Accrued professional and legal fees		58,954		70,450
	Deferred income		127,190		146,038
	Other		162,565		178,702
		$	1,062,988	$	1,276,963

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8. Commitments and Contingencies
	The Company and its subsidiaries are from time to time involved in ordinary and routine litigation. Management presently believes that the ultimate outcome of these proceedings, individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, cash flows or result of operations. Nevertheless, litigation is subject to inherent uncertainties and an unfavorable ruling could occur.  An unfavorable ruling could include money damages and in such event, could result in a material adverse impact on the Company’s results of operations in the year in which the ruling occurs.
	On July 19, 2011, Misonix entered into a Distribution Agreement (the “Distribution Agreement”) with Puricore, Inc. (“Puricore”). Pursuant to the Distribution Agreement, the Company had been granted the right to distribute PuriCore’s Vashe ® solution products in the United States, on a private label basis and known as the Misonix Soma product, as an antibacterial, antimicrobial irrigating solution for the treatment of human wound care in conjunction with therapeutic ultrasonic procedures (the “Field”). PuriCore had agreed, subject to modification, not to sell the products that were the subject of the Distribution Agreement (the “Licensed Products”) to any other therapeutic ultrasound company for distribution in the Field in the United States (“Exclusivity”). The Company had agreed not to sell or distribute in the United States in the Field any irrigating solution that has anti-microbial properties other than the Licensed Products so long as the Company had Exclusivity.
	During our fiscal fourth quarter 2013, the Company sent a notice to terminate the Distribution Agreement due to management’s belief that the products subject to the Distribution Agreement were non-conforming. Puricore disputed the Company’s ability to terminate the Distribution Agreement. On October 11, 2013, the Company and Puricore mutually terminated the Distribution Agreement and signed a Settlement Agreement resolving all issues without the payment of any monies by either party. A reversal of the previously accrued and unpaid contractual minimum gross profit requirement in the amount of $439,508 was made through cost of goods sold in the quarter ended December 31, 2013 as a result of the Settlement Agreement.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	9. Fair Value of Financial Instruments
	We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of “observable inputs” and minimize the use of “unobservable inputs.” The three levels of inputs used to measure fair value are as follows:
	Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.
	Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.
	The following is a summary of the carrying amounts and estimated fair values of our financial instruments at December 31, 2013 and June 30, 2013:
	31-Dec-13	Carrying Amount		Fair Value
	Cash and cash equivalents	$	5,033,526	$	5,033,526
	Trade accounts receivable		2,870,988		2,870,988
	Trade accounts payable		1,154,838		1,154,838
	30-Jun-13	Carrying Amount		Fair Value
	Cash and cash equivalents	$	5,806,437	$	5,806,437
	Trade accounts receivable		2,974,641		2,974,641
	Trade accounts payable		2,208,999		2,208,999
	The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:
	Cash and cash equivalents
	The carrying amount approximates fair value because of the short maturity of those instruments.
	Trade Accounts Receivable
	The carrying amount of trade receivables reflects net recovery value and approximates fair value because of their short outstanding terms.
	Trade Accounts Payable
	The carrying amount of trade payables approximates fair value because of their short outstanding terms.
	Non-financial assets and liabilities
	Certain non-financial assets and liabilities, principally goodwill, are measured at fair value on a non-recurring basis; that is the assets and liabilities are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances, such as when evidence of impairment exists. At December 31, 2013, no fair value adjustments or material fair value measurements were required for non-financial assets or liabilities.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	6 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	10. Goodwill and Intangible Assets
	Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or product lines. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur and determination of our weighted-average cost of capital. We primarily use a discounted cash flow model in determining fair value, which consists of level three inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company determined that there were no indicators that the recorded goodwill was impaired as of December 31, 2013 which required further testing.
	The cost of acquiring or processing patents is capitalized. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $599,789 and $568,823 at December 31, 2013 and June 30, 2013, respectively. Accumulated amortization totaled $595,965 and $554,923 at December 31, 2013 and June 30, 2013, respectively. Amortization expense for the three month periods ended December 31, 2013 and 2012 was approximately $21,000 and $18,000, respectively. Amortization expense for the six month periods ended December 31, 2013 and 2012 was approximately $41,000 and $35,000, respectively.
	Net customer relationships reported in intangible and other assets totaled $280,000 and $360,000 at December 31, 2013 and June 30, 2013, respectively. Accumulated amortization amounted to $520,000 at December 31, 2013 and $440,000 at June 30, 2013. Amortization expense for the three month periods ended December 31, 2013 and 2012 was $40,000. Amortization expense for the six month periods ended December 31, 2013 and 2012 was $80,000. Customer relationships are amortized on a straight-line basis over a five year period.
	The following is a schedule of estimated future amortization expense as of December 31, 2013:
				Customer
		Patents		Relationships
	2014	$	44,701	$	80,000
	2015		81,224		160,000
	2016		75,707		40,000
	2017		73,524		-
	2018		70,467		-
	Thereafter		254,166		-
		$	599,789	$	280,000

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
	Dec. 31, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	11. Recent Accounting Pronouncements
	There have been no recently issued pronouncements that have had or are expected to have a material impact on our financial statements.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	12. Related Party Transactions
	Stavros G. Vizirgianakis was appointed to the Company’s Board of Directors on May 7, 2013. Mr. Vizirgianakis owns a controlling interest in MD Solutions Australasia PTY Ltd and a family member owns one hundred percent of Applied BioSurgical; both independent distributors for the Company. The Company’s distribution agreements with these companies pre-date Mr. Vizirgianakis’ appointment to the Board of Directors.
	Set forth below is a table showing the Company’s net sales and accounts receivable for the indicated time periods below:
	For the six months ended December 31,
	Applied Bio Surgical	2013		2012
	Sales	$	165,694	$	312,230
	Accounts Receivable	$	29,425	$	108,069
	MD Solutions Australasia PTY Ltd.	2013		2012
	Sales	$	75,353	$	280,679
	Accounts Receivable	$	14,913	$	143,237
	For the three months ended December 31,
	Applied Bio Surgical	2013		2012
	Sales	$	72,118	$	105,547
	Accounts Receivable	$	29,425	$	108,069
	MD Solutions Australasia PTY Ltd.	2013		2012
	Sales	$	32,013	$	140,779
	Accounts Receivable	$	14,913	$	143,237

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Discontinued Operations, Policy [Policy Text Block]	'
	Discontinued Operations
	Laboratory and Forensic Safety Products Business
	On October 19, 2011, Misonix sold its Laboratory and Forensic Safety Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The earn-out will not be factored into the gain on sale until it is earned by Misonix. As of December 31, 2013, no earn-out has been recorded.
	High Intensity Focused Ultrasound Technology
	In consideration for the May 2010 sale of the rights to its high intensity focused ultrasound technology to USHIFU LLC (“USHIFU”), Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received by USHIFU related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to the $5.8 million. Commencing 90 days after each December 31stand beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Total payments through December 31, 2013 were $504,788.
	Results of Discontinued Operations
		For the three months ended				For the six months ended
		December 31,				December 31,
		2013		2012		2013		2012
	Revenues	$	4,975	$	4,975	$	9,950	$	9,950
	Income from discontinued operations, before tax	$	4,975	$	3,475	$	9,950	$	9,793
	Income tax expense		-		-		-		-
	Net income from discontinued operations, net of tax	$	4,975	$	3,475	$	9,950	$	9,793
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	Certain prior period amounts in the accompanying financial statements and related notes have been reclassified to conform to the current period’s presentation.

Basis_of_Presentation_Tables

Basis of Presentation (Tables)	6 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
	The following is an analysis of net sales from continuing operations by geographic region:
		Three months ended December 31,						Six months ended December 31,
		2013		2012				2013			2012
	United States	$	1,827,543	$	1,635,550	United States		$	3,408,813		$	4,085,160
	Australia		32,013		141,774	Australia			75,353			281,674
	Europe		369,701		958,388	Europe			753,291			1,720,299
	Asia		870,793		361,556	Asia			1,337,060			783,783
	Canada and Mexico		347,640		29,922	Canada and Mexico			432,345			255,982
	South America		434,983		108,462	South America			710,604			406,388
	South Africa		72,118		105,584	South Africa			165,694			312,267
	Middle East		167,268		132,995	Middle East			314,483			199,203
		$	4,122,059	$	3,474,231			$	7,197,643		$	8,044,756
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		For the three months ended				For the six months ended
		December 31,				December 31,
		2013		2012		2013			2012
	Revenues	$	4,975	$	4,975	$	9,950		$	9,950
	Income from discontinued operations, before tax	$	4,975	$	3,475	$	9,950		$	9,793
	Income tax expense		-		-		-			-
	Net income from discontinued operations, net of tax	$	4,975	$	3,475	$	9,950		$	9,793

Income_Loss_Per_Share_of_Commo1

Income (Loss) Per Share of Common Stock (Tables)	6 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
	The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:
		For the six months ended		For the three months ended
		December 31,		December 31,
		2013	2012	2013	2012
	Basic shares	7,189,136	7,012,734	7,195,406	7,020,107
	Dilutive effect of stock options	-	-	517,497	-
	Diluted shares	7,189,136	7,012,734	7,712,903	7,020,107

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The fair values of the options granted during the six months ended December 31, 2013 and 2012 were estimated on the date of the grant using the Black-Scholes option-pricing model on the basis of the following weighted average assumptions during the respective periods:
			For the six months ended
			December 31,
			2013				2012
	Risk-free interest rate			3	%			2.5	%
	Expected option life in years			6.5				6.5
	Expected stock price volatility			76.09	%			75.1	%
	Expected dividend yield			0	%			0	%
	Weighted-average fair value of options granted		$	3.95			$	2.94
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Changes in outstanding stock options during the six months ended December 31, 2013 were as follows:
			Options
						Weighted
						Average
				Weighted		Remaining
				Average		Contractual		Aggregate
			Number of	Exercise		Life		Intrinsic
			Shares	Price ($)		(years)		Value (a)
	Outstanding as of June 30, 2013		1,729,991	3.65
	Granted		324,000	4.94
	Exercised		-40,712	3.21
	Forfeited		-19,250	4.64
	Expired		-162,200	4.67
	Outstanding as of December 31, 2013		1,831,829	3.78		5.6		$	3,644,848
	Exercisable and vested at December 31, 2013		1,101,555	3.68		4.3		$	2,353,430
	Available for grant at December 31, 2013		549,975
	(a)	Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at December 31, 2013 or if exercised, the exercise dates, exceeds the exercise prices of the respective options.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories are summarized as follows:
		December 31,		June 30,
		2013		2013
	Raw material	$	2,029,216	$	2,641,982
	Work-in-process		604,841		394,629
	Finished goods		2,797,511		2,358,943
			5,431,568		5,395,554
	Less valuation reserve		1,461,596		1,361,077
		$	3,969,972	$	4,034,477

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]	'
	The following summarizes accrued expenses and other current liabilities:
		December 31,		June 30,
		2013		2013
	Accrued payroll and vacation	$	406,279	$	456,095
	Accrued bonuses		100,000		225,000
	Accrued commissions		208,000		200,678
	Accrued professional and legal fees		58,954		70,450
	Deferred income		127,190		146,038
	Other		162,565		178,702
		$	1,062,988	$	1,276,963

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Carrying Values and Estimated Fair Values of Financial Instruments [Table Text Block]	'
	The following is a summary of the carrying amounts and estimated fair values of our financial instruments at December 31, 2013 and June 30, 2013:
	31-Dec-13	Carrying Amount		Fair Value
	Cash and cash equivalents	$	5,033,526	$	5,033,526
	Trade accounts receivable		2,870,988		2,870,988
	Trade accounts payable		1,154,838		1,154,838
	30-Jun-13	Carrying Amount		Fair Value
	Cash and cash equivalents	$	5,806,437	$	5,806,437
	Trade accounts receivable		2,974,641		2,974,641
	Trade accounts payable		2,208,999		2,208,999

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	The following is a schedule of estimated future amortization expense as of December 31, 2013:
				Customer
		Patents		Relationships
	2014	$	44,701	$	80,000
	2015		81,224		160,000
	2016		75,707		40,000
	2017		73,524		-
	2018		70,467		-
	Thereafter		254,166		-
		$	599,789	$	280,000

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	6 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Set forth below is a table showing the Company’s net sales and accounts receivable for the indicated time periods below:
	For the six months ended December 31,
	Applied Bio Surgical	2013		2012
	Sales	$	165,694	$	312,230
	Accounts Receivable	$	29,425	$	108,069
	MD Solutions Australasia PTY Ltd.	2013		2012
	Sales	$	75,353	$	280,679
	Accounts Receivable	$	14,913	$	143,237
	For the three months ended December 31,
	Applied Bio Surgical	2013		2012
	Sales	$	72,118	$	105,547
	Accounts Receivable	$	29,425	$	108,069
	MD Solutions Australasia PTY Ltd.	2013		2012
	Sales	$	32,013	$	140,779
	Accounts Receivable	$	14,913	$	143,237

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net sales	$4,122,059	$3,474,231	$7,197,643	$8,044,756
UNITED STATES	'	'	'	'
Net sales	1,827,543	1,635,550	3,408,813	4,085,160
AUSTRALIA	'	'	'	'
Net sales	32,013	141,774	75,353	281,674
SOUTH AFRICA	'	'	'	'
Net sales	72,118	105,584	165,694	312,267
EUROPE	'	'	'	'
Net sales	369,701	958,388	753,291	1,720,299
ASIA	'	'	'	'
Net sales	870,793	361,556	1,337,060	783,783
SOUTH AMERICA	'	'	'	'
Net sales	434,983	108,462	710,604	406,388
MIDDLE EAST	'	'	'	'
Net sales	$167,268	$132,995	$314,483	$199,203

Basis_of_Presentation_Details_

Basis of Presentation (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenues	$4,975	$4,975	$9,950	$9,950
Income from discontinued operations, before tax	4,975	3,475	9,950	9,793
Income tax expense	0	0	0	0
Net income from discontinued operations, net of tax	$4,975	$3,475	$9,950	$9,793

Basis_of_Presentation_Details_1

Basis of Presentation (Details Textual) (USD $)	1 Months Ended		6 Months Ended
	Oct. 19, 2011	31-May-10	Dec. 31, 2013	Dec. 31, 2013
	Laboratory and Forensic Safety Products Business [Member]	High Intensity Focused Ultrasound Technology [Member]	High Intensity Focused Ultrasound Technology [Member]	Fibra Sonics Ny Inc [Member]
Equity Method Investment, Ownership Percentage	'	'	'	100.00%
Proceeds from Sales of Business, Affiliate and Productive Assets	$1,500,000	'	'	'
Sale of Business Potential Additional Payment	500,000	'	'	'
Sale of Business Potential Additional Payment Determination Basis	'based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”).	'	'	'
Proceeds from Sales of Intangible Assets	'	5,800,000	'	'
Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to First Benchmark	'	7.00%	'	'
Proceeds from Sale of Intangible Assets First Benchmark	'	3,000,000	'	'
Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to Second Benchmark	'	5.00%	'	'
Proceeds from Sale of Intangible Assets Second Benchmark	'	5,800,000	'	'
Payment Sale Of Intangible Assets Description	'	'Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million.	'	'
Payment Sale Of Intangible Assets	'	'	$504,788	'

Income_Loss_Per_Share_of_Commo2

Income (Loss) Per Share of Common Stock (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Basic shares	7,195,406	7,020,107	7,189,136	7,012,734
Dilutive effect of stock options	517,497	0	0	0
Diluted shares	7,712,903	7,020,107	7,189,136	7,012,734

Income_Loss_Per_Share_of_Commo3

Income (Loss) Per Share of Common Stock (Details Textual)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	543,080	1,922,905	1,831,829	1,922,905

Comprehensive_LossIncome_Detai

Comprehensive (Loss)/Income (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net Income (Loss) Attributable to Parent	$459,338	($653,769)	($424,664)	($608,935)

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Risk-free interest rate	3.00%	2.50%
Expected option life in years	'6 years 6 months	'6 years 6 months
Expected stock price volatility	76.09%	75.10%
Expected dividend yield	0.00%	0.00%
Weighted-average fair value of options granted	$3.95	$2.94

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Employee Stock Option [Member], USD $)	6 Months Ended
	Dec. 31, 2013
Employee Stock Option [Member]	'
Number of Shares, Outstanding at beginning of period	1,729,991
Number of Shares, Granted	324,000
Number of Shares, Exercised	-40,712
Number of Shares, Forfeited	-19,250
Number of Shares, Expired	-162,200
Number of Shares, Outstanding at end of period	1,831,829
Number of Shares, Exercisable and vested	1,101,555
Number of shares, Available for grant	549,975
Weighted Average Exercise Price, Outstanding at beginning of period	$3.65
Weighted Average Exercise Price, Granted	$4.94
Weighted Average Exercise Price, Exercised	$3.21
Weighted Average Exercise Price, Forfeited	$4.64
Weighted Average Exercise Price, Expired	$4.67
Weighted Average Exercise Price, Outstanding at end of period	$3.78
Weighted Average Exercise Price, Exercisable and vested	$3.68
Weighte Average Remaining Contractual Life, Outstanding (in years)	'5 years 7 months 6 days
Weighte Average Remaining Contractual Life, Exercisable and vested (in years)	'4 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$3,644,848	[1]
Aggregate Intrinsic Value, Exercisable and vested (in dollars)	$2,353,430	[1]
[1]	Intrinsic value for purposes of this table represents the amount by which the fair value of the underlying stock, based on the respective market prices at December 31, 2013 or if exercised, the exercise dates, exceeds the exercise prices of the respective options.

StockBased_Compensation_Detail2

Stock-Based Compensation (Details Textual) (USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	'not to exceed 10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period	324,000	342,500
Allocated Share-based Compensation Expense	$325,000	$221,000
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options	2,143,000	'
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1	'3 years 2 months 12 days	'
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	$130,555	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Tax Expense (Benefit)	$2,750	$2,329	$5,500	$3,829
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	'	'	1.00%	'

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Raw material	$2,029,216	$2,641,982
Work-in-process	604,841	394,629
Finished goods	2,797,511	2,358,943
Inventory, Gross	5,431,568	5,395,554
Less valuation reserve	1,461,596	1,361,077
Inventory, Net, Total	$3,969,972	$4,034,477

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Accrued payroll and vacation	$406,279	$456,095
Accrued bonuses	100,000	225,000
Accrued commissions	208,000	200,678
Accrued professional and legal fees	58,954	70,450
Deferred income	127,190	146,038
Other	162,565	178,702
Accrued Expenses and Other Current Liabilities	$1,062,988	$1,276,963

Commitment_and_Contingencies_D

Commitment and Contingencies (Details Textual) (USD $)	3 Months Ended
	Dec. 31, 2013
Minimum Gross Profit	$439,508

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2012
Cash and cash equivalents, Carrying Amount	$5,033,526	$5,806,437	$6,855,047	$6,273,015
Trade accounts receivable, Carrying Amount	2,870,988	2,974,641	'	'
Trade accounts payable, Carrying Amount	1,154,838	2,208,999	'	'
Cash and cash equivalents, Fair Value	5,033,526	5,806,437	'	'
Trade accounts receivable, Fair Value	2,870,988	2,974,641	'	'
Trade accounts payable, Fair Value	$1,154,838	$2,208,999	'	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Patents [Member]	'	'
2014	$44,701	'
2015	81,224	'
2016	75,707	'
2017	73,524	'
2018	70,467	'
Thereafter	254,166	'
Finite-Lived Intangible Assets, Future Amortization Expense	599,789	568,823
Customer Relationships [Member]	'	'
2014	80,000	'
2015	160,000	'
2016	40,000	'
2017	0	'
2018	0	'
Thereafter	0	'
Finite-Lived Intangible Assets, Future Amortization Expense	$280,000	$360,000

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013
Patents [Member]	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'17 years	'	'
Finite-Lived Intangible Assets, Net, Total	$599,789	'	$599,789	'	$568,823
Finite-Lived Intangible Assets, Accumulated Amortization	595,965	'	595,965	'	554,923
Amortization of Intangible Assets	21,000	18,000	41,000	35,000	'
Customer Relationships [Member]	'	'	'	'	'
Finite-Lived Intangible Assets, Net, Total	280,000	'	280,000	'	360,000
Finite-Lived Intangible Assets, Accumulated Amortization	520,000	'	520,000	'	440,000
Amortization of Intangible Assets	$40,000	$40,000	$80,000	$80,000	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Applied Bio Surgical [Member]	'	'	'	'
Sales	$72,118	$105,547	$165,694	$312,230
Accounts receivable	29,425	108,069	29,425	108,069
MD Solutions Australasia PTY Ltd [Member]	'	'	'	'
Sales	32,013	140,779	75,353	280,679
Accounts receivable	$14,913	$143,237	$14,913	$143,237